DaVita Stock Plunges 18% Despite Beating Earnings Estimates - Here's Why

What Happened

After the closing bell on August 4, DaVita (DVA), the largest US kidney dialysis provider, reported second-quarter results that looked solid on the surface.

• Adjusted EPS: $4.02, above the $3.84 consensus estimate
• Revenue: $3.55 billion, ahead of the $3.49 billion analysts expected
• Adjusted operating income: $579 million, with free cash flow of $256 million

By the headline numbers, this was a clean beat on both lines. But the stock did the opposite of what a beat is supposed to do. Shares opened roughly 4% lower in after-hours trading, and the selling accelerated through the August 5 regular session, ending the day down close to 18% - DaVita's worst single-day drop this year.

Why a Beat Turned Into an 18% Selloff — It Was About the Quality of the Revenue

The headline numbers weren't the problem. What spooked investors were the details underneath them.

• Revenue per treatment slipped. This figure fell roughly $2 sequentially. In a business like DaVita's, built on repeat treatments for a largely fixed patient base, revenue per treatment - not total revenue - is the number that best captures underlying profitability. A decline here signals pricing and mix pressure even as overall volume holds up.
• Patient care costs stayed elevated. Per-treatment costs remained high through the first half of the year, meaning much of the extra revenue was absorbed by higher costs rather than flowing to margin.
• "Reaffirmed" guidance read as a letdown. Management kept its full-year 2026 adjusted EPS guidance at $14.10-$15.20, unchanged from before. The midpoint, $14.65, sits below the Street's $14.88 consensus. Simply holding guidance steady - rather than raising it - was enough to disappoint a market that had priced in an upgrade.
• The second half looks tougher, not easier. Management flagged that revenue per treatment could turn slightly negative year-over-year in the back half, citing a shrinking commercial-insurance mix, lower phosphate-binder revenue, and a tough comparison against a one-time revenue boost in the second half of last year.

Put together, the beat reflected the quarter that already happened, while the stock price reflects the profitability trajectory ahead. When investors saw that trajectory getting harder, not easier, the headline beat lost its power to support the stock.

What to Take Away From This

• A beat on EPS and revenue doesn't automatically mean a good quarter. DaVita cleared both bars and still had its worst day of the year. Always look past the headline numbers to the margin, pricing, and cost trends buried in the details - that's usually where the real story is.
• "Guidance reaffirmed" and "guidance raised" are different signals. When the market is already expecting an upgrade, simply holding guidance steady can read as a disappointment, even though nothing was technically cut. Check where the guidance midpoint sits relative to consensus, not just whether it moved.
• For recurring-revenue businesses, watch the per-unit economics, not just top-line growth. In companies built on repeat service to a defined customer or patient base - subscription models, healthcare providers, and similar businesses - the direction of revenue-per-unit often matters more to the stock than overall revenue growth.

For related context, see: Eli Lilly Stock Jumps 6% on 48% Revenue Surge, Novo Nordisk Stock Falls 6% Despite Raised Guidance

Sources

This article synthesizes and analyzes the reporting below in our own words - it is not a reproduction of the original text. For the latest figures and full detail, please refer to the original sources.

• Why is DaVita stock sliding today? - Investing.com
• DaVita Q2 Earnings Call Highlights - Yahoo Finance
• Earnings call transcript: DaVita beats Q2 2026 estimates but shares fall - Investing.com

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data yourself before making any investment decision.